RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Clinical trials for RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Triple-Drug attack on stomach cancer shows promise in major trial

Disease control Not yet recruiting

This study tests whether adding a second immunotherapy drug (ipilimumab) to the standard combination of sintilimab and chemotherapy helps shrink stomach tumors before surgery and keeps cancer from coming back afterward. About 720 adults with resectable stomach or gastroesophageal…

Matched conditions: RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase: PHASE2, PHASE3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Get alerted when new RESECTABLE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

Triple-Drug attack on stomach cancer shows promise in major trial